Lyell Wealth Management LP Sells 4,427 Shares of DexCom, Inc. (NASDAQ:DXCM)

Lyell Wealth Management LP decreased its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 6.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 60,613 shares of the medical device company's stock after selling 4,427 shares during the quarter. Lyell Wealth Management LP's holdings in DexCom were worth $4,714,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Blue Whale Capital LLP raised its holdings in DexCom by 91.9% during the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company's stock valued at $15,821,000 after buying an additional 113,000 shares in the last quarter. Taylor Frigon Capital Management LLC raised its stake in shares of DexCom by 51.6% in the 3rd quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company's stock valued at $2,182,000 after acquiring an additional 11,075 shares in the last quarter. Brooktree Capital Management acquired a new stake in DexCom in the 3rd quarter worth approximately $683,000. National Pension Service boosted its position in DexCom by 4.1% during the third quarter. National Pension Service now owns 949,743 shares of the medical device company's stock worth $63,671,000 after purchasing an additional 37,363 shares during the period. Finally, Intact Investment Management Inc. acquired a new position in DexCom during the third quarter valued at approximately $650,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Analysts Set New Price Targets

DXCM has been the subject of a number of analyst reports. Wells Fargo & Company boosted their price objective on shares of DexCom from $90.00 to $94.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 11th. Raymond James cut their target price on shares of DexCom from $115.00 to $99.00 and set a "strong-buy" rating for the company in a research report on Friday, October 25th. StockNews.com downgraded DexCom from a "buy" rating to a "hold" rating in a research report on Saturday, November 2nd. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Finally, JPMorgan Chase & Co. raised their target price on DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a report on Friday, October 25th. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $99.06.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the business's stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now owns 83,526 shares of the company's stock, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm's stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares of the company's stock, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 38,083 shares of company stock valued at $3,309,794. 0.30% of the stock is currently owned by company insiders.

DexCom Price Performance

NASDAQ:DXCM traded down $0.56 during mid-day trading on Friday, hitting $88.78. The company's stock had a trading volume of 3,729,437 shares, compared to its average volume of 3,632,823. The company has a market capitalization of $34.69 billion, a price-to-earnings ratio of 62.08, a P/E/G ratio of 2.31 and a beta of 1.14. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The stock has a fifty day moving average of $83.26 and a 200-day moving average of $75.94.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.